Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
132.87
-0.32 (-0.24%)
At close: Jul 3, 2025, 1:00 PM
132.63
-0.25 (-0.18%)
After-hours: Jul 3, 2025, 1:05 PM EDT
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
19.47B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,605 | 35 | 0.46% |
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BIIB News
- 5 days ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - GlobeNewsWire
- 8 days ago - New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA - GlobeNewsWire
- 10 days ago - Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results - GlobeNewsWire
- 12 days ago - Biogen: Investors Are Missing The Bigger Picture - Seeking Alpha
- 17 days ago - 20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks - Market Watch
- 17 days ago - Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - GlobeNewsWire
- 23 days ago - Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity - GlobeNewsWire
- 25 days ago - Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha